Background
Methods
Subjects and design
water | Age | gender | times | diagnosis | isodose curve (%) | total cGy | volume (cc) | collimater (cc) | response | water | age | gender | times | diagnosis | isodose curve (%) | total cGy | volume (cc) | collimater (cc) | response | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | placebo | 76 | M | 3 3 | HCC | 80 75 | 3,900 3,900 | 2.521 2.746 | 7.5 7.5 | NR | HW | 52 | M | 3 | liver meta of colon ca | 74 | 3,600 | 12.283 | 15 | NR | |
2 | placebo | 82 | M | 1 | HCC | 70 | 1,200 | 11.769 | 20 | CR | HW | 56 | M | 3 | liver meta of colon ca | 85 | 3,600 | 2.552 | 12.5 | PR | |
3 | placebo | 57 | F | 3 | bile duct ca | 80 | 3,000 | 40.334 | 30 | PR | HW | 77 | F | 3 | liver meta of colon ca | 75 | 3,000 | 107.136 | 20 | CR | |
4 | placebo | 47 | F | 9 | liver meta. of sarcoma | 80 82 84 | 3,600 3,600 3,900 | 10.628 6.542 2.673 | 25 20 15 | NR | HW | 57 | M | 3 | HCC | 70 | 3,600 | 47.679 | 15 | NR | |
5 | placebo | 50 | F | 3 | liver meta of colon ca | 80 | 3,900 | 16.237 | 20 | NR | HW | 66 | M | 3 | HCC | 80 | 3,600 | 16.216 | 25 | PR | |
6 | placebo | 21 | F | 3 | liver meta. of ovarian ca | 85 | 3,600 | 29.398 | 30 | CR | HW | 57 | M | 3 | HCC | 80 | 3,600 | 35.303 | 30 | NR | |
7 | placebo | 65 | M | 3 | liver meta. of rectal ca | 70 | 3,000 | 182.871 | 40 | PR | HW | 47 | M | 3 | HCC | 77 | 3,000 | 17.65 | 20 | CR | |
8 | placebo | 73 | M | 3 | liver meta. of rectal ca | 75 | 3,600 | 37.937 | 20 | PR | HW | 49 | M | 3 | HCC | 80 | 3,300 | 53.578 | 12.5 | PR | |
9 | placebo | 58 | M | 3 | liver meta. of pancreatic ca | 75 | 3,000 | 65.637 | 35 | CR | HW | 71 | F | 3 | HCC | 85 | 3,000 | 3.861 | 10 | NR | |
10 | placebo | 64 | M | 3 | HCC | 70 | 3,000 | 140.136 | 20 | PR | HW | 45 | M | 3 | HCC | 80 | 3,600 | 28.286 | 15 | NR | |
11 | placebo | 65 | F | 3 | HCC | 70 | 3,600 | 48.645 | 25 | PR | HW | 45 | F | 3 | liver meta. of gastric ca | 85 | 3,000 | 38.938 | 15 | PR | |
12 | placebo | 80 | M | 3 | HCC | 80 | 3,000 | 209.954 | 25 | NR | HW | 56 | F | 3 | Adrenal metastasis of HCC | 80 | 3,600 | 9.494 | 15 | PR | |
13 | placebo | 56 | M | 3 | HCC | 85 | 3,600 | 15.365 | 15 | CR | HW | 49 | M | 3 | Adrenal metastasis of HCC | 75 | 3,000 | 91.223 | 20 | NR | |
14 | placebo | 61 | F | 3 | HCC | 70 | 3,000 | 98.957 | 30 | NR | HW | 60 | M | 3 | LN metastasis of HCC | 75 | 3,000 | 120.366 | 25 | NR | |
15 | placebo | 46 | M | 3 | HCC | 80 | 3,000 | 20.848 | 25 | CR | HW | 47 | M | 3 | LN metastasis of HCC | 80 | 3,000 | 80.459 | 25 | NR | |
16 | placebo | 70 | F | 3 | HCC | 85 | 3,600 | 16.908 | 20 | PR | HW | 50 | M | 3 | HCC | 75 | 3,600 | 29.422 | 20 | NR | |
17 | placebo | 44 | M | 3 | HCC | 85 | 3,600 | 16.612 | 30 | NR | HW | 49 | F | 3 | HCC | 70 | 3,000 | 156.289 | 40 | PR | |
18 | placebo | 48 | M | 3 | HCC | 85 | 3,000 | 35.093 | 20 | NR | HW | 63 | F | 3 | HCC | 75 | 3,900 | 5.425 | 20 | NR | |
19 | placebo | 76 | F | 3 | HCC | 85 | 3,600 | 5.75 | 15 | NR | HW | 51 | M | 3 | HCC | 70 | 4,000 | 28.637 | 35 | NR | |
20 | placebo | 60 | M | 3 | HCC | 83 | 3,600 | 6.802 | 12.5 | NR | HW | 67 | F | 3 | HCC | 80 | 3,600 | 20.122 | 20 | PR | |
21 | placebo | 77 | M | 3 | HCC | 75 | 3,300 | 33.282 | 25 | PR | HW | 56 | M | 3 | HCC | 70 | 3,600 | 23.5 | 20 | CR | |
22 | placebo | 55 | M | 3 | HCC | 83 | 3,600 | 11.963 | 20 | NR | HW | 78 | F | 3 | HCC | 83 | 3,600 | 26.456 | 25 | NR | |
23 | placebo | 57 | M | 3 | HCC | 70 | 3,000 | 75.782 | 40 | NR | HW | 56 | M | 3 | HCC | 77 | 3,600 | 31.908 | 20 | CR | |
24 | placebo | 65 | M | 2 | HCC | 75 | 3,000 | 55.191 | 25 | NR | HW | 60 | M | 3 | HCC | 70 | 3,600 | 36.479 | 30 | PR | |
HW | 70 | M | 3 | HCC | 76 | 3,600 | 63.434 | 40 | NR |
QOL Assessment
Biomarker analysis
Assessment of response
Statistical analysis
Results
Hydrogen water improved the QOL of patients receiving radiotherapy
Hydrogen water mitigated oxidative stress marker during radiotherapy
Hydrogen water did not compromise the radiation treatment efficacies
Hydrogen treatment did not alter liver function or blood composition during radiotherapy
Placebo | Hydrogen water | |||||
---|---|---|---|---|---|---|
all (n = 25) | male (n = 17) | female (n = 8) | all (n = 25) | male (n = 16) | female (n = 9) | |
AST(IU/L) | ||||||
Week 0 | 24.8 ± 9.1 | 25.6 ± 5.7 | 23.1 ± 10.4 | 25.3 ± 6.7 | 25.9 ± 5.3 | 23.9 ± 8.3 |
Week 6 | 26.3 ± 6.7 | 26.9 ± 7.1 | 25.4 ± 6.8 | 26.8 ± 8.2 | 27.2 ± 9.9 | 26.4 ± 5.1 |
ALT(IU/L) | ||||||
Week 0 | 27.4 ± 15 | 28.1 ± 11 | 26.5 ± 17 | 26.9 ± 8.7 | 27.1 ± 6.7 | 26.7 ± 10.3 |
Week 6 | 28.8 ± 14 | 28.7 ± 16 | 27.6 ± 12 | 28.1 ± 6.5 | 28.8 ± 7.3 | 27.6 ± 9.9 |
γ-GPT(IU/L) | ||||||
Week 0 | 61.9 ± 54.3 | 62.3 ± 35.6 | 60.5 ± 64.7 | 62.3 ± 26.2 | 62.1 ± 34.8 | 62.4 ± 47.9 |
Week 6 | 62.8 ± 22.8 | 63.2 ± 16.5 | 62.7 ± 25.9 | 63.6 ± 36.2 | 63.9 ± 54.2 | 63.2 ± 27.4 |
AST(IU/L) | ||||||
Week 0 | 24.8 ± 9.1 | 25.6 ± 5.7 | 23.1 ± 10.4 | 25.3 ± 6.7 | 25.9 ± 5.3 | 23.9 ± 8.3 |
Week 6 | 26.3 ± 6.7 | 26.9 ± 7.1 | 25.4 ± 6.8 | 26.8 ± 8.2 | 27.2 ± 9.9 | 26.4 ± 5.1 |
Placebo | Hydrogen water | |||||
---|---|---|---|---|---|---|
all (n = 25) | male (n = 17) | female (n = 8) | all (n = 25) | male (n = 16) | female (n = 9) | |
The number of leukocytes (× 102 /μL) | ||||||
Week 0 | 55.8 ± 15.6 | 58.5 ± 12.7 | 52.8 ± 16.4 | 56.2 ± 16.7 | 57.3 ± 17.2 | 55.4 ± 15.1 |
Week 6 | 53.9 ± 21.4 | 54.1 ± 22.7 | 53.7 ± 19.8 | 54.7 ± 28.7 | 55.1 ± 31.2 | 53.8 ± 19.4 |
The number of erythrocytes (× 104 /μL) | ||||||
Week 0 | 474.2 ± 38.3 | 492.3 ± 45.8 | 460.8 ± 30.5 | 482.5 ± 42.1 | 496.6 ± 50.7 | 472.9 ± 36.4 |
Week 6 | 462.1 ± 52.4 | 473.8 ± 42.1 | 456.4 ± 62.2 | 479.5 ± 36.5 | 486.4 ± 29.4 | 470.7 ± 40.5 |
The number of thrombocytes (×104 /μL) | ||||||
Week 0 | 25.7 ± 6.5 | 26.4 ± 4.7 | 24.7 ± 5.9 | 26.4 ± 7.1 | 26.9 ± 5.5 | 26.1 ± 4.8 |
Week 6 | 24.5 ± 4.7 | 25.9 ± 2.8 | 23.4 ± 6.4 | 25.7 ± 4.8 | 26.1 ± 4.7 | 25.3 ± 3.9 |